A previously healthy 28-year-old woman was admitted under a diagnosis of acute myocarditis. Six hours after admission, circulatory support using intraaortic balloon pumping and percutaneous cardiopulmonary support were introduced, because uncontrollable ventricular arrhythmia appeared unexpectedly. Subsequently, decreased peripheral platelet count appeared, in spite of improved hemodynamics. Therefore, a left ventricular assist device was implanted and she was weaned from the percutaneous cardiopulmonary support. On the fifth postoperative day, she was successfully weaned from the left ventricular assist device with full recovery of myocardial function. Myocardial biopsy demonstrated the appearance of acute viral myocarditis. This case suggests that the left ventricular assist device might offer effective circulatory support for acute fulminant myocarditis.

Download full-text PDF

Source

Publication Analysis

Top Keywords

left ventricular
16
ventricular assist
16
assist device
16
circulatory support
8
percutaneous cardiopulmonary
8
cardiopulmonary support
8
ventricular
5
[fulminant myocarditis
4
myocarditis treated
4
left
4

Similar Publications

Aims: To investigate the distribution of left atrioventricular coupling index (LACI) among patients with heart failure and left ventricular ejection fraction (LVEF)<50% and to explore its association with the combined endpoint of all-cause death or HF hospitalization at long term follow-up.

Methods And Results: Patients with HF and LVEF<50% undergoing cardiac magnetic resonance (CMR) were evaluated. Patients with atrial fibrillation or flutter were excluded.

View Article and Find Full Text PDF

Background: Cardiac magnetic resonance (CMR) is essential for diagnosing cardiomyopathy, serving as the gold standard for assessing heart chamber volumes and tissue characterization. Hemodynamic forces (HDF) analysis, a novel approach using standard cine CMR images, estimates energy exchange between the left ventricular (LV) wall and blood. While prior research has focused on peak or mean longitudinal HDF values, this study aims to investigate whether unsupervised clustering of HDF curves can identify clinically significant patterns and stratify cardiovascular risk in non-ischemic LV cardiomyopathy (NILVC).

View Article and Find Full Text PDF

Rationale: Patients with atrial fibrillation and a large goiter have high perioperative risks and often cannot tolerate general anesthesia, making it necessary for us to explore new safe and effective anesthesia methods.

Patient Concerns: The patient presented with atrial fibrillation accompanied by rapid ventricular rate, a thrombus attached to the left atrial appendage, and a massive thyroid goiter compressing the airway.

Diagnosis: After the left humerus fracture surgery, the patient's internal fixation loosened and fractured, accompanied by infection, formation of sinus tracts, and suppuration.

View Article and Find Full Text PDF

Data on outcomes of extracorporeal membrane oxygenation (ECMO) are limited in patients with pulmonary atresia intact ventricular septum (PAIVS). The objective of this study was to describe the use of ECMO and the associated outcomes in patients with PAIVS. We retrospectively reviewed neonates with PAIVS who received ECMO between 2009 and 2019 in 19 US hospitals affiliated with the Collaborative Research for the Pediatric Cardiac Intensive Care Society (CoRe-PCICS).

View Article and Find Full Text PDF

Aims: A cardiovascular magnetic resonance (CMR) approach to non-invasively estimate left ventricular (LV) filling pressure was recently developed and shown to correlate with invasively measured pulmonary capillary wedge pressure (PCWP). We examined the association between CMR-estimated PCWP (CMR-PCWP) and other imaging and biomarker measures of congestion, and the effect of empagliflozin on these, in the SUGAR-DM-HF trial (NCT03485092).

Methods And Results: SUGAR-DM-HF enrolled 105 patients with heart failure with reduced ejection fraction (HFrEF) and pre-diabetes or type 2 diabetes who were randomly assigned to empagliflozin 10 mg or placebo once daily for 36 weeks.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!